Answer:
w = 2, EF = 30 , FG = 42
Explanation:
We have EF = 5w + 20 and FG = 7w + 28
Since these points E, F and G are col-linear points we have.
EG = EF + FG
And given that EG = 72
So, EF+EG = 72
5w + 20 + 7w + 28 = 72
12w + 48 = 72
12 w = 24
w = 2
So EF = 5w + 20 = 5x2 + 20 = 30
FG = 7w + 28 = 7x2 + 28 = 42
44 percent of 25 is 11 to get percentage u would take 44 and divide it by a hundred and u would get .44 and then u would multiply that by 25 and u get 11
sdfsdf
4) 
Multiply by 2 on both sides
3m + 15 = 45
Subtract both sides by 15
3m = 30
Divide both sides by 3
so m = 3
5) 
Multiply both sides by 8
168 = q + 35
Subtract both sides by 35
q = 133
6) 
Subtract 14 from both sides

multiply by -11 on both sides
4x = 572
Divide both sides by 4
x= 143
7) 
Add 6 on both sides

Multiply both sides by 5
3c = 75
Divide both sides by 3
c = 25
8) 
Subtract both sides by 17

Multiply both sides by -2
t = -52
9) 
Multiply both sides by -7
42= 5p + 2
subtract 2 from both sides
40 = 5p
Divide both sides by 5
so p = 8
Answer:
The answer is rule 6
Step-by-step explanation:
Answer:
If we reject the null hypothesis based on the evidence, then our conclusion should be Option c.
If we do not reject the null hypothesis based on the evidence, then our conclusion should be Option a.
Step-by-step explanation:
We are given that the FDA wants to set up a hypothesis test to show that the new drug is safe before approving it by assuming it to be unsafe.
So, Null hypothesis,
= New drug is unsafe
Alternate Hypothesis,
= New drug is safe
<em>Now, if we reject the null hypothesis based on the evidence, then our conclusion should be that : </em>
There is sufficient evidence to believe that the new drug is safe because rejecting null hypothesis means that alternate hypothesis is accepted with required evidence.
<em>And If we do not reject the null hypothesis based on the evidence, then our conclusion should be that : </em>
There is insufficient evidence to believe that the new drug is safe because not rejecting null hypothesis means that we are not ready with enough evidence to assume that new drug is safe.